Thrusting Cambridge biopharma business Arecor is planning a UK IPO. The company is advancing a robust portfolio of partnered and proprietary treatments from existing therapies to enable healthier lives. Diabetes is a prime area.
Tony Quested of Business Weekly writes:
Arecor CEO Sarah Howell said the IPO would enable the company to advance the development of its internal proprietary diabetes and specialty hospital products to a defined value inflexion point prior to potential partnering.
Read the full story on Business Weekly
